Literature DB >> 9724989

Radical surgery for early gastric cancer.

J L Whiting1, J W Fielding.   

Abstract

The role of radical surgery for early gastric cancer has become a topic of considerable debate. Despite excellent results from Japan and several retrospective and uncontrolled trials, results from two large prospective randomized trials appear to demonstrate no benefit from D2 compared to the D1 resections. These trials have prompted a move away from radical lymph-node dissection. We argue that this reasoning is flawed and based not on the lack of efficacy of the D2 resection but in an attempt to reduce post-operative mortality and morbidity. Post-operative complications are largely a result of distal pancreatectomy and splenectomy and the relative inexperience of surgeons performing the operations. By preserving these organs and concentrating surgery to specialized centres the complication rate of radical surgery can be significantly reduced to approximate that of non-radical surgery. Lymph-node metastasis to the N2 nodes in early gastric cancer has been shown to be as high as 23%. Non-radical surgery poses significant risks of leaving residual disease. Radical surgery must remain the operation of choice if non-curative surgery for a curable condition is to be avoided.

Entities:  

Mesh:

Year:  1998        PMID: 9724989     DOI: 10.1016/s0748-7983(98)80002-4

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

Review 1.  Function-preserving surgery for gastric cancer.

Authors:  Hitoshi Katai
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

2.  Linear stapling of the short gastric vessels reduces blood loss and splenectomy at oesophageal and gastric surgery.

Authors:  J F Dowdall; O J McAnena
Journal:  Surg Endosc       Date:  2006-01-19       Impact factor: 4.584

Review 3.  Early gastric cancer: concepts, diagnosis, and management.

Authors:  Hitoshi Katai; Takeshi Sano
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.